Meningococcal B vaccination: real-world experience and future perspectives.
Invasive meningococcal disease (IMD) represents a severe risk for health. It can be considered the most dangerous vaccine-preventable disease due to the high probability of related permanent sequelae and death. The introduction in many countries of the conjugate vaccines against A, C, W135, and Y meningococcal serogroups influenced significantly the impact of the disease. Recently, the difficulties in obtaining an effective vaccine against meningococcal serogroup B (MenB) have been get over through the reverse vaccinology, enabling the recognition of some antigens providing a response against most of circulating MenB strains worldwide. The new 4cMenB vaccine is recommended in Europe, Canada, Australia, the USA, and some Latin American countries. Even if sound data on efficacy and safety profile are available, the results in terms of effectiveness are still limited. The management of the MenB outbreaks in two US universities demonstrated the ability to quickly achieve high vaccination coverage rates and no new cases among immunized subjects were assessed. It is desirable that the opportunity to complete preventive intervention against IMD offered by the new 4cMenB vaccine should be recognized and that this vaccine is included in the vaccination schedule to complete the panel of immunization against Neisseria meningitidis.
a Department of Medical Sciences , University of Ferrara , Ferrara , Italy.
Parvanè
P
Kuhdari
a Department of Medical Sciences , University of Ferrara , Ferrara , Italy.
Armando
A
Stefanati
a Department of Medical Sciences , University of Ferrara , Ferrara , Italy.
Silvia
S
Lupi
a Department of Medical Sciences , University of Ferrara , Ferrara , Italy.
Nicoletta
N
Valente
a Department of Medical Sciences , University of Ferrara , Ferrara , Italy.
Giovanni
G
Gabutti
D004196:Disease Outbreaks / Q000517:prevention & control*; D006801:Humans; D008589:Meningococcal Infections / Q000276:immunology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000276:immunology
C570015:4CMenB vaccine; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate
Immunization; Meningococcal disease; Neisseria meningitides; Serogroup B